Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
J Gastrointest Oncol ; 7(2): 234-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27034791

ABSTRACT

BACKGROUND: Combination chemotherapy regimens including fluoropyrimidines as well as albumin-bound paclitaxel have shown promising results in patients with metastatic pancreatic adenocarcinoma (mPC). Based on the recently described excellent therapeutic index of capecitabine plus nab-paclitaxel in metastatic breast cancer, the present phase II trial was initiated. METHODS: Patients with previously untreated mPC were treated with capecitabine (825 mg/m(2) orally bid on days 1-15) and nab-paclitaxel (125 mg/m(2) intravenously on days 1 and 8) every 3 weeks. In patients without clinically relevant adverse reactions after the 1st treatment course (≤ grade 2 toxicities according to NCI-CTC vs. 4.0, exuding alopecia and fatigue of any degree) and adequate bone marrow function, the nab-paclitaxel dose was escalated to 100 mg/m(2) on days 1, 8 and 15 of each cycle; this intra-individual dose escalation was maintained during subsequent treatment courses if tolerated. The primary endpoint was objective response rate (ORR) according to RECIST criteria, assessed by an independent radiological review committee with evaluation performed every 2 months. RESULTS: Between 12/2013 and 01/2015, 30 patients were entered in this monocentric academic phase II trial. All patients had an ECOG performance status of 0-1, 80% had liver metastases and 23% had biliary stents in place at time of study initiation. Median CA19-9 was 1,004 U/mL (0.9-100.000 U/mL). In all patients except 2, a dose escalation of nab-paclitaxel after the 1st treatment course could be accomplished. The most common grade 3 adverse events (AEs) included transient sensory neuropathy (23%), (afebrile) neutropenia (17%), hand-foot-syndrome (13%) and phototoxic skin reaction (10%). Among 29 RECIST-response assessable patients, the ORR was 41.4% and stable disease (SD) was noted in 34.5%, resulting in a disease control rate (DCR) of 76%. After a median follow-up duration of 10.3 months (range, 1.9-19.0 months), 13/30 patients (43.3%) are presently being alive. CONCLUSIONS: The combination of capecitabine + nab-paclitaxel at these doses and scheduling was well tolerated and showed substantial antitumor efficacy.

2.
Wien Klin Wochenschr ; 124(3-4): 111-23, 2012 Feb.
Article in German | MEDLINE | ID: mdl-22382553

ABSTRACT

Immune Thrombocytopenia (ITP) is a rare and - in most patients - mild disease, but might be associated with severe or even life-threatening bleeding complications. The treatment of ITP has partly changed in recent years, due to new therapeutic options. International guidelines changed accordingly. This consensus statement by the Austrian Society of Hematology and Oncology (OEGHO) is not a new evaluation of the current evidence, but rather tries to discuss the available international guidelines and adapt them to the situation in Austria. The subject is primary ITP in adults only. Classification, epidemiology, clinical presentation and diagnostics of ITP, and especially the management of this disease, are discussed in detail. This includes current aspects of first, second, and third line therapies, splenectomy with its indications and contraindications, and the use of new therapeutic options like thrombopoetin receptor agonists (TRA).


Subject(s)
Hematology/standards , Medical Oncology/standards , Practice Guidelines as Topic , Purpura, Thrombocytopenic, Idiopathic/diagnosis , Purpura, Thrombocytopenic, Idiopathic/therapy , Adult , Austria , Consensus Development Conferences as Topic , Humans
3.
J Immunother ; 32(6): 638-54, 2009.
Article in English | MEDLINE | ID: mdl-19483645

ABSTRACT

Cryopreservation of immature or mature dendritic cells (DC) has been proposed as a suitable method to gain large numbers of DC for immunotherapeutic trials against cancer. However, clinical studies using cryopreserved DC have demonstrated only limited success so far. The aim of this study was to investigate whether cryopreservation of monocytes elicits more potent DC and whether these DC are comparable to freshly generated DC preparations. Monocytes, either separated immunomagnetically or by means of leukapheresis and elutriation, were differentiated into DC and cryopreserved at various developmental stages. DC preparations were analyzed regarding recovery, viability, phenotype, and functional properties. In contrast to DC frozen at their immature or semi-mature state, generation of DC from cryopreserved monocytes elicited viability values comparable with freshly generated DC. Furthermore, using frozen monocytes for DC differentiation revealed improved expression of DC surface markers and interleukin-12p70 secretion as compared with DC generated from frozen immature or frozen semi-mature DC. Impaired phenotypical appearance of the latter DC variants was further substantiated by functional analysis. T-cells cocultured with these DC showed decreased expression of interferon-gamma and granzyme B, and lowered proliferation when compared with T-cells cocultured with DC generated from frozen monocytes or DC generated from freshly isolated monocytes. Induction of regulatory T-cell populations was negligible among all investigated DC preparations. These findings may further improve DC-based immunotherapeutical protocols. Cryopreservation of unchallenged monocytes enables targeted therapy by loading DC with varying antigenic compositions in case of tumor escape during treatment.


Subject(s)
Dendritic Cells/immunology , Immunotherapy, Adoptive , Monocytes/immunology , Neoplasms/therapy , T-Lymphocytes, Regulatory/immunology , Antigens, CD/immunology , Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/immunology , Antigens, Differentiation, T-Lymphocyte/metabolism , Cancer Vaccines/immunology , Cell Line, Tumor , Cryopreservation , Dendritic Cells/transplantation , Humans , Immunomagnetic Separation , Interferon-gamma/immunology , Interferon-gamma/metabolism , Interleukin-10/immunology , Interleukin-10/metabolism , Interleukin-12/immunology , Interleukin-12/metabolism , Interleukin-4/immunology , Interleukin-4/metabolism , Lectins, C-Type , Monocytes/transplantation , T-Lymphocytes, Regulatory/metabolism
4.
Oncol Rep ; 21(6): 1585-92, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19424640

ABSTRACT

Immunotherapy with autologous dendritic cells (DCs) loaded with tumor lysate(s) from allogeneic tumor cell lines is a novel strategy to induce immune responses in cancer patients. We report on a pilot trial of autologous DCs pulsed with tumor cell lysate derived from allogeneic medullary thyroid carcinoma (MTC) cell lines in patients with metastatic MTC. The purpose of this study was to assess the safety, resulting immune responses and clinical activity of the DCs. DCs were injected into a groin lymph node at 3-week intervals. Monitoring included serial calcitonin tumor marker measurements, radiological imaging and immunological in vitro tests (T-cell interferon-gamma detection assay, T-cell cytotoxicity assay). Ten patients (median age 47 years, range 29-77) were enrolled. DC vaccinations were well-tolerated and safe. After a median follow-up of 11 months, (range 7-26), 3 (30%) of 10 patients had stable disease, while 7 (70%) of the patients progressed during treatment. In 2 patients with stable disease, calcitonin decreased below treatment levels, paralleled by a T-cell-mediated immune response. Notably, treatment with DCs pulsed with a combination of different tumor cell lysates was followed by a calcitonin decrease in 4 patients who had previously experienced a calcitonin increase during monotherapy with DCs pulsed with a single lysate. Allogeneic tumor cell lysate-based DC immunotherapy is well-tolerated and safe. Combined treatment with different tumor cell lysate-pulsed DCs increases the likelihood of a calcitonin tumor marker response and should therefore be preferred over monotherapy with DCs pulsed with a single lysate.


Subject(s)
Carcinoma, Medullary/therapy , Dendritic Cells/transplantation , Immunotherapy, Adoptive , Thyroid Neoplasms/therapy , Adult , Aged , Biomarkers, Tumor/blood , Calcitonin/blood , Cancer Vaccines , Carcinoma, Medullary/diagnosis , Carcinoma, Medullary/immunology , Carcinoma, Medullary/secondary , Cell Line, Tumor , Dendritic Cells/immunology , Disease Progression , Female , Humans , Immunotherapy, Adoptive/adverse effects , Interferon-gamma/metabolism , Male , Middle Aged , Pilot Projects , T-Lymphocytes, Cytotoxic/immunology , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/immunology , Thyroid Neoplasms/secondary , Time Factors , Transplantation, Autologous , Treatment Outcome
5.
Dis Colon Rectum ; 51(6): 852-7, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18317841

ABSTRACT

PURPOSE: The treatment of high anal fistula using endorectal advancement flaps represents an important technique to attain cure of fistulation and preserve anal continence. The creation of the advancement flap may comprise the rectal mucosa only or involve the full transection of the rectal wall. A comparison between full-thickness flaps and mucosal (partial-thickness) flaps was made to analyze the defining elements of successful fistula treatment: recurrence rates and anal continence. METHODS: A retrospective review of 54 consecutive patients with high anal fistula of cryptoglandular origin was undertaken. Patient risk was categorized according to previous anal surgery. Continence was assessed according to the Vaizey score. Recurrence rates were recorded in a long-term, complete follow-up. RESULTS: Thirty-four patients underwent surgery using a partial-thickness flap; in 20 patients the full-thickness flap was used. There were no major intraoperative or postoperative complications. Continence scores revealed significant incontinence in 11.1 percent of all patients. Full transection of the rectal wall for flap creation did not pose a threat to continence. Twenty-four percent of all patients suffered from a recurrence. Patients with four or more previous anal surgeries were at highest risk for failure. A single patient in the full-thickness flap group (5 percent) as opposed to 12 patients (35.3 percent) in the partial-thickness group suffered from recurrence. CONCLUSION: The comparison of partial-thickness to full-thickness endorectal advancement flaps suggests an improvement of recurrence rates without higher incontinence rates when a full mobilization of the rectal wall is performed.


Subject(s)
Rectal Fistula/surgery , Surgical Flaps , Adult , Aged , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Postoperative Complications , Retrospective Studies , Treatment Outcome
6.
Eur J Cancer ; 44(6): 866-75, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18296042

ABSTRACT

Maintenance of telomere length has been reported to be an absolute requirement for unlimited growth of human tumour cells and in about 85% of cases, this is achieved by reactivation of telomerase, the enzyme that elongates telomeres. Only in rare cases, like in human medullary thyroid carcinomas (MTC), telomerase activity (TA) is low or undetectable; however, this does not limit tumours to become clinically significant. Here, we report that very low TA (below 5% of HEK293) observed in MTC cell strains derived from different patients, although not sufficient for immortalising the cells, is necessary for prolonging their replicative life span. Telomere erosion led to induction of a crisis period after long-term in vitro cultivation, which was reached earlier when treating the cells with MST-312, a telomerase inhibitor at non-toxic concentrations. Crisis was bypassed either by ectopic hTERT introduction or by infrequent spontaneous immortalisation, the latter of which was always associated with telomerase reactivation and changes of the cellular phenotype. While confirming the high importance of telomerase for tumour development, these data draw attention to the relevance of low TA: although insufficient for telomere stabilisation, it allows MTC cells to reach more population doublings, increasing both cell numbers as well as the risk of accumulating mutations and thus might support the development of clinically significant MTC.


Subject(s)
Carcinoma, Medullary/enzymology , Neoplasm Proteins/metabolism , Telomerase/metabolism , Thyroid Neoplasms/enzymology , Carcinoma, Medullary/pathology , Disease Progression , Humans , Reverse Transcriptase Polymerase Chain Reaction/methods , Telomere/pathology , Thyroid Neoplasms/pathology , Tumor Cells, Cultured
7.
Leuk Lymphoma ; 49(2): 237-46, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18231909

ABSTRACT

Peripheral T-cell lymphomas (PTCL) have a variable outcome. We have investigated the prognostic value of molecular staging in non-anaplastic PTCL. T-cell receptor gamma rearrangements were routinely determined in peripheral blood (n = 40) and bone marrow (n = 38) of patients with PTCL (75% unspecified) by conventional PCR at diagnosis. Tissue controls for PCR included 24 tumour biopsies. Twenty-four patients (60%) had a PCR-detectable clonal TCR gamma rearrangement in PB or BM. These TCR gamma PCR positive patients had significantly more stage IV disease (14 patients of 15 patients; P = 0.001), elevated LDH (14 of 18 patients; P = 0.04), higher IPI (16 of 21 patients; P = 0.03), more anemia (15 of 19 patients; P = 0.02) and lower platelet counts (seven of seven patients; P = 0.02). Clinical outcome of this clonal group was characterised by lower complete remission rates (37.5% vs. 62.5%), and overall response rates (58.3% vs. 87.5%; P < 0.05) as well as a significantly shorter median overall survival (12.8 vs. 30.0 months; P = 0.006). Patients with clinical stages I - III but molecular stage IV had an equally poor overall survival when compared with patients with clinical stage IV (15.8 vs. 13.9 months). In contrast, patients with CS I - III in the absence of a TCR gamma rearrangement in PB or BM had a favourable outcome with an estimated overall survival of 70% at 3 and 5 years. Molecular staging in PB and BM by TCR gamma PCR at diagnosis may serve as a useful prognostic tool in PTCL.


Subject(s)
Gene Rearrangement , Lymphoma, T-Cell, Peripheral/diagnosis , Receptors, Antigen, T-Cell, gamma-delta/genetics , Adult , Aged , Aged, 80 and over , Blood Cells , Bone Marrow , Female , Humans , Lymphoma, T-Cell, Peripheral/mortality , Male , Middle Aged , Polymerase Chain Reaction , Prognosis , Remission Induction , Survival Rate , Treatment Outcome
8.
Cancer Immunol Immunother ; 57(6): 859-70, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18030468

ABSTRACT

BACKGROUND: Recent preclinical and clinical evidence suggests the use of allogeneic tumor as a source of antigen for DC-based immunotherapy against cancer. We hypothesized that addition of allogeneic tumor lysate to monocyte-derived DC culture could serve a dual purpose: (1) antigen source and (2) protein supplementation of DC culture media. Protein supplementation whether of known origin (human serum/plasma, fetal bovine serum, human serum albumin) or undeclared origin ("serum-free" media) is a source of variability and bias. We addressed the question whether protein supplementation can be omitted in the presence of allogeneic tumor lysate. MATERIALS AND METHODS: Human DC cultured in the presence of lysate from medullary thyroid carcinoma (MTC) cell line SHER-I (TuLy-DC) and DC pulsed with the same lysate but cultured in the presence of FBS (FBS-DC) were assessed for morphology, phenotype, maturation and functional properties. RESULTS: In comparison of FBS-DC/TuLy-DC no significant differences in morphology, phenotype and maturation could be detected. Both culture conditions produced CD1a(high), CD14(low) DC with high expression of costimulatory molecules and CD83 upon stimulation. TuLy-DC gave significantly better yields and produced more IL12p70. DC showed high (allo)stimulatory capacity toward T-cells. TuLy-DC induced more intracellular IFNgamma in CD8+T-cells of vaccinated MTC patients. Both types of DC induced killing of SHER-I after short in vitro restimulation. Tumor lysate from SHER-I can substitute for further protein supplementation in DC culture. Allogeneic tumor lysates should be taken into consideration as both source of antigen and protein supplementation in monocyte-derived DC culture.


Subject(s)
Antigens, Neoplasm/chemistry , Carcinoma/immunology , Dendritic Cells/cytology , Immunotherapy/methods , Neoplasms/immunology , Proteins/chemistry , Thyroid Neoplasms/immunology , Transplantation, Homologous/methods , CD3 Complex/biosynthesis , Carcinoma/metabolism , Cell Culture Techniques/methods , Cell Line, Tumor , Culture Media, Serum-Free/pharmacology , Humans , Interleukin-10/metabolism , Interleukin-4/metabolism , Thyroid Neoplasms/metabolism
9.
J Clin Endocrinol Metab ; 91(11): 4571-7, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16954161

ABSTRACT

BACKGROUND: In vitro and in vivo studies have shown that dendritic cells (DCs) can stimulate antitumor T cell responses against medullary thyroid carcinoma (MTC). However, despite promising results in selected cases, the clinical efficacy of DC immunotherapy in patients with MTC has been limited. Recently, it has been demonstrated in mice that heat shock enhances the capacity of bone-marrow-derived DCs to stimulate antigen-specific T cells. The aim of our investigations was to evaluate whether heat shock also increases the capacity of human monocyte-derived DCs to stimulate antitumor T cell responses against MTC tumor cells. METHODS: DCs from six patients with metastatic MTC were pulsed with tumor lysate derived from allogeneic MTC tumor cells and were heat shocked for 12 h at 40 C or kept at 37 C. Thereafter, the DCs were matured and cocultured with T cells. Finally, the cytotoxic activity of T cells against MTC tumor cells was measured in vitro. RESULTS: In all patient samples, cytotoxic T cell responses against MTC tumor cells could be induced. Notably, heat-shocked DCs were more potent stimulators of cytotoxic T cell responses than control DCs, with T cells stimulated with heat-shocked DCs displaying a significantly increased cytotoxic activity against MTC tumor cells as compared with T cells stimulated with control DCs. In none of the experiments was a cytotoxic T cell response against unrelated pancreatic tumor cells (PANC-1) observed, using both control and heat-shocked DCs. CONCLUSIONS: Our study shows that heat-shocking DCs may be a valuable strategy to increase the immunostimulatory capacity of DCs used for immunotherapy of MTC.


Subject(s)
Carcinoma, Medullary/immunology , Dendritic Cells/metabolism , Dendritic Cells/pathology , Hyperthermia, Induced/methods , T-Lymphocytes, Cytotoxic/metabolism , Thyroid Neoplasms/immunology , Adult , Aged , Antigens, Surface/metabolism , Carcinoma, Medullary/pathology , Carcinoma, Medullary/therapy , Cell Differentiation , Cell Extracts/immunology , Female , Genes, MHC Class I , HLA Antigens/metabolism , HSP70 Heat-Shock Proteins/metabolism , HSP90 Heat-Shock Proteins/metabolism , Heat-Shock Response , Humans , Immunotherapy/methods , In Vitro Techniques , Lymphocyte Activation/immunology , Male , Middle Aged , Thyroid Neoplasms/pathology , Thyroid Neoplasms/therapy , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/metabolism , Tumor Cells, Cultured
10.
Eur J Immunol ; 36(2): 361-70, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16402404

ABSTRACT

Toll-like receptors (TLR) represent an ancient front-line defence system that enables the host organism to sense the presence of microbial components within minutes. As inducers of inflammation, TLR act as important triggers of distinct entities such as sepsis or autoimmune disease exacerbation. We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion. Despite 1,25(OH)(2)D3-induced up-regulation of CD14, challenge of human monocytes with either LPS or lipoteichoic acid resulted in impaired TNF-alpha and procoagulatory tissue factor (CD142) production, emphasizing the critical role of TLR in the induction of inflammation. Moreover, reduced TLR levels in 1,25(OH)(2)D3-treated phagocytes were accompanied by impaired NF-kappaB/RelA translocation to the nucleus and by reduced p38 and p42/44 (extracellular signal-regulated kinase 1/2) phosphorylation upon TLR-ligand engagement. Both TLR down-regulation and CD14 up-regulation were substantially inhibited by the vitamin D receptor (VDR) antagonist ZK 159222, indicating that the immunomodulatory effect of 1,25(OH)(2)D3 on innate immunity receptors requires VDR transcription factor activation. Our data provide strong evidence that 1,25(OH)(2)D3 primes monocytes to respond less effectively to bacterial cell wall components in a VDR-dependent mechanism, most likely due to decreased levels of TLR2 and TLR4.


Subject(s)
Cholecalciferol/pharmacology , Down-Regulation/drug effects , Macrophage Activation/drug effects , Monocytes/immunology , Toll-Like Receptor 2/biosynthesis , Toll-Like Receptor 4/biosynthesis , Active Transport, Cell Nucleus/drug effects , Active Transport, Cell Nucleus/immunology , Calcitriol/analogs & derivatives , Calcitriol/pharmacology , Cells, Cultured , Cholecalciferol/immunology , Dose-Response Relationship, Drug , Down-Regulation/immunology , Humans , Inflammation/immunology , Inflammation/metabolism , Inflammation/pathology , Lipopolysaccharide Receptors/biosynthesis , Lipopolysaccharide Receptors/immunology , Lipopolysaccharides/immunology , Lipopolysaccharides/pharmacology , Macrophage Activation/immunology , Mitogen-Activated Protein Kinase 1/immunology , Mitogen-Activated Protein Kinase 1/metabolism , Monocytes/metabolism , Monocytes/pathology , Phosphorylation/drug effects , Receptors, Calcitriol/antagonists & inhibitors , Receptors, Calcitriol/immunology , Receptors, Calcitriol/metabolism , Signal Transduction/drug effects , Signal Transduction/immunology , Teichoic Acids/immunology , Teichoic Acids/pharmacology , Toll-Like Receptor 2/immunology , Toll-Like Receptor 4/immunology , Transcription Factor RelA/immunology , Transcription Factor RelA/metabolism , Up-Regulation/drug effects , Up-Regulation/immunology , p38 Mitogen-Activated Protein Kinases/immunology , p38 Mitogen-Activated Protein Kinases/metabolism
11.
Clin Chim Acta ; 364(1-2): 139-47, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16051207

ABSTRACT

BACKGROUND: The mechanism of action of mycophenolic acid (MPA) has been described as a blockade of inosine 5'-monophosphate dehydrogenase (IMPDH) and is thought to selectively influence T- and B-lymphocytes due to their strong dependency on guanine nucleotides synthesized via the de novo purine synthesis pathway. Recent evidence suggests MPA to affect antigen-presenting cells. METHODS: Using CD14+ derived human dendritic cells (DC) we have investigated the effects of MPA on differentiation, maturation and function and studied intracellular nucleotide content and IMPDH activity. RESULTS: GTP content and IMPDH activities of DC were strongly and dose-dependently decreased when MPA was present during the entire culture period or was added after the fifth (immature DC) or the seventh (mature DC) day of culture. Concurrent to low GTP levels, a dose-dependent reduction in the expression of CD80, CD86, CD40, CD54 and CD83 was seen which was accompanied by a decreased capacity of DC to stimulate T-cells. Our data for the first time shows a direct effect of MPA on the maturation and function of human CD14+ derived DC, indicates a role of IMPDH and a dependency on the de novo purine synthesis pathway.


Subject(s)
Dendritic Cells/drug effects , IMP Dehydrogenase/antagonists & inhibitors , Mycophenolic Acid/pharmacology , Adenosine Triphosphate/metabolism , Antigens, CD/analysis , Biomarkers/analysis , Cell Differentiation/drug effects , Cell Differentiation/immunology , Cell Proliferation/drug effects , Cells, Cultured , Dendritic Cells/cytology , Dendritic Cells/immunology , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Flow Cytometry , Guanosine Triphosphate/metabolism , Humans , IMP Dehydrogenase/metabolism , Immunophenotyping , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology
12.
Anticancer Res ; 25(6B): 4225-30, 2005.
Article in English | MEDLINE | ID: mdl-16309220

ABSTRACT

BACKGROUND: Medullary thyroid carcinoma (MTC) is a calcitonin-producing tumor of the parafollicular C-cells, accounting for 5-10% of all thyroid tumors. To date, the only effective treatment is the early and total surgical removal of all neoplastic tissue. As the prognosis of patients with advanced MTC, unresectable or distant metastases is poor, and chemotherapy or irradiation is of no significant value, alternative strategies have been sought. MATERIALS AND METHODS: A promising treatment approach for human MTC, that has already been introduced at our facility, is based on vaccination with autologous dendritic cells (DCs). Strong evidence that vaccination with autologous tumor lysate-pulsed DCs induces a specific immune response in vivo has been provided. However, the therapeutic success of this approach is sometimes critically limited by the small amount of tumor material available, especially from patients operated at an early tumor stage. Thus, it would be to the best advantage to have sufficient amounts of autologous tumor cells available for DC pulsing. RESULTS: A method to generate viable autologous tumor cell cultures from a variety of MTC tissue samples, even when the sample size is small, has been successfully established. These cell lines maintain their neuroendocrine phenotype. In addition, it can be shown that these cells also display the biological features of neuroendocrine tumor cells at the molecular level. CONCLUSION: The unlimited availability of these MTC cell lines makes it possible to specify cancerogenesis of MTC. In addition, the availability of sufficient amounts of tumor lysate from these cell lines offers the advantage of prolonged immunotherapy. Finally, these cell lines could be elegantly used as read-out system to monitor the in vivo immune response during immunotherapy with DC cell-based vaccination in patients suffering from MTC.


Subject(s)
Cancer Vaccines/immunology , Carcinoma, Medullary/immunology , Carcinoma, Medullary/therapy , Immunotherapy, Adoptive/methods , Thyroid Neoplasms/immunology , Thyroid Neoplasms/therapy , Animals , Cancer Vaccines/therapeutic use , Carcinoma, Medullary/pathology , Cell Line, Tumor , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Thyroid Neoplasms/pathology
13.
Hum Gene Ther ; 16(4): 435-44, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15871675

ABSTRACT

We have previously demonstrated that mutant vaccinia viruses target tumors in vivo after systemic delivery, and they have potential as vectors for tumor-directed gene therapy. We hypothesized that hyperthermia may augment vaccinia delivery to tumors after systemic injection, as hyperthermia increases the permeability of the endothelial vasculature to nanoparticles. In our in vitro experiments, we have shown that hyperthermia does not alter tumor cells' susceptibility to the intrinsic cytopathogenicity of the vaccinia virus compared with normothermic controls. Hyperthermia also does not change the viral infectivity or the level of viral marker gene expression when compared with normothermia. In an in vitro model of endothelial cell monolayer permeability, we have demonstrated that hyperthermia increases the permeability of the monolayer to vaccinia virus and that this phenomenon is completely reversible. In vivo we have demonstrated that the tumors that were treated with systemic vaccinia under conditions of hyperthermia (41.5 degrees C for 30 min) had significantly higher levels of vaccinia marker gene activity (>100-fold) than those treated under normothermic conditions (p < 0.05) and that this effect was specific to tumor. We also demonstrated that mice with 1 cm subcutaneous tumors treated with a systemically delivered, conditionally replicating vaccinia under conditions of hyperthermia had complete tumor regression in 50% and significantly improved antitumor response, compared with normothermic viral-treated controls (mean tumor volume of 110 mm(3) vs 3169 mm(3), 13 days after treatment) and compared with hyperthermic, nonvirally treated control animals (p < 0.0001). Regional hyperthermia improves vaccinia targeting to tumors, and thereby enhances the antitumor response.


Subject(s)
Genetic Therapy/methods , Genetic Vectors/administration & dosage , Hyperthermia, Induced/methods , Neoplasms, Experimental/virology , Vaccinia virus/genetics , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Cell Membrane Permeability , Drug Screening Assays, Antitumor/methods , Endothelial Cells/virology , Endothelium, Vascular/cytology , Endothelium, Vascular/virology , Gene Expression , Genetic Vectors/genetics , Humans , Mice , Mice, Inbred C57BL , Neoplasms, Experimental/genetics , Neoplasms, Experimental/therapy , Tumor Cells, Cultured
14.
World J Gastroenterol ; 10(16): 2447-51, 2004 Aug 15.
Article in English | MEDLINE | ID: mdl-15285041

ABSTRACT

AIM: Gastrointestinal autonomic nerve tumors are uncommon stromal tumors of the intestinal tract. Their histological appearance is similar to that of other gastrointestinal stromal tumors. We report two cases and performed an analysis of the literature by comparing our findings with the available case reports in the medical literature. METHODS: Two patients were admitted with abdominal tumor masses. One occurred in the stomach with large multiple liver metastases and the second originated in Meckel's diverticulum. The latter site has never been reported previously. Both patients underwent surgery. In one patient gastrectomy, right liver resection and colon transversum resection were performed to achieve aggressive tumor debulking. In the other patient the tumor bearing diverticulum was removed. RESULTS: Postoperative recovery of both patients was uneventful. Histological examination, immunohistochemical analysis and electron microscopy revealed the diagnosis of a gastrointestinal autonomic nerve tumor. The patient with the tumor in Meckel's diverticulum died 6 mo after surgery because of pneumonia. The patient with liver metastases have been alive 13 years after initial tumor diagnosis and 7 years after surgery with no evidence of tumor progression. In light of our results, we performed a thorough comparison with available literature reports. CONCLUSION: Radical surgical resection of gastrointestinal autonomic nerve tumors seems to be the only available curative approach to date, and long term survival is possible even in large metastasized tumors.


Subject(s)
Gastrointestinal Neoplasms/surgery , Nervous System Neoplasms/surgery , Adult , Aged , Biomarkers/analysis , Digestive System/innervation , Female , Gastrointestinal Neoplasms/diagnostic imaging , Gastrointestinal Neoplasms/pathology , Humans , Immunohistochemistry , Male , Neoplasm Metastasis/pathology , Tomography, X-Ray Computed
15.
Clin Cancer Res ; 10(9): 2944-53, 2004 May 01.
Article in English | MEDLINE | ID: mdl-15131029

ABSTRACT

PURPOSE: Prognosis and treatment effectiveness for medullary thyroid carcinoma (MTC) are strictly related to tumor stage. Palliative treatment options show no significant benefit. A promising treatment approach for human cancer is based on the vaccination of autologous dendritic cells (DCs). EXPERIMENTAL DESIGN: The objective of this study was to evaluate the effectiveness of DC vaccines in MTC patients. Therefore, we generated autologous tumor lysate-pulsed DCs from 10 patients suffering from advanced MTC for repeated vaccination. Mature DCs were derived from peripheral blood monocytes by using CD14 magnetic bead selection and subsequent culture in the presence of granulocyte macrophage colony-stimulating factor, interleukin 4, and tumor necrosis factor alpha with or without addition of IFN-gamma. DCs were loaded with tumor lysate and further injected into a groin lymph node. Toxicity, tumor marker profile, immune response, and clinical response were determined. RESULTS: Vaccination was well tolerated and induced a positive immunological response in all of the tested patients as evaluated by in vivo delayed-type hypersensitivity reactivity or in vitro intracytoplasmic IFN-gamma detection assay. Three patients had a partial response, 1 patient presented a minor response, and 2 patients showed stable disease. The remaining 4 patients had progressive disease. CONCLUSIONS: These data provide strong evidence that vaccination with tumor-lysate pulsed DCs results in the induction of a specific immune response in patients suffering from MTC. Objective clinical responses could be observed even for far-advanced disease. Therefore, we suggest that MTC is particularly suited for DC-based immunotherapy.


Subject(s)
Cancer Vaccines/administration & dosage , Carcinoma, Medullary/therapy , Dendritic Cells/immunology , Thyroid Neoplasms/therapy , Adult , Aged , Calcitonin/blood , Cancer Vaccines/immunology , Carcinoembryonic Antigen/blood , Carcinoma, Medullary/blood , Carcinoma, Medullary/pathology , Female , Flow Cytometry , Humans , Immunophenotyping , Immunotherapy, Adoptive/methods , Male , Middle Aged , Survival Analysis , Thyroid Neoplasms/blood , Thyroid Neoplasms/pathology , Time Factors , Treatment Outcome
16.
Int J Oncol ; 24(3): 609-13, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14767545

ABSTRACT

Heat shock proteins (HSPs) are known to be of crucial importance in host-tumor interactions. The goal of this study was to determine whether there was an increase in HSP expression in a patient suffering from unresectable hepatocellular carcinoma treated with percutaneous radiofrequency (RF) ablation. Immediately before RF ablation, a computed tomography (CT)-guided core needle biopsy (diameter, 18 gauge) was obtained from the tumor. The RF ablation was then performed using a saline-perfused RF ablation system (diameter of RF electrode, 15 gauge; ablation time, 10 min). Twenty-four hours after tumor ablation, core needle biopsy was repeated, and biopsy specimens were obtained from the residual tumor margin visible on contrast-enhanced CT. For both procedures, no side effects or clinically relevant complications were observed. The specimens were mapped by immunohistochemistry, determining the cellular expression of HSP 70 and HSP 90. After RF ablation, in the cytoplasm and at the tumor cell surface, an 8-fold increase in HSP 70 and a 1.2-fold increase in HSP 90 was observed, respectively. In the cell nucleus, the HSP 90 expression before RF ablation was 10%, and decreased to 0% after RF ablation. We have demonstrated that, following RF ablation, cellular expression of HSP 70 and HSP 90 in hepatocellular carcinoma is increased. We further suggest that routing of HSP 90 from the nucleus to the cell surface occurred after RF ablation. This may be of relevance in further therapeutic anti-tumor strategies.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/therapy , Heat-Shock Proteins/biosynthesis , Liver Neoplasms/metabolism , Liver Neoplasms/therapy , Biopsy, Needle , Carcinoma, Hepatocellular/pathology , Catheter Ablation , Electrodes , HSP70 Heat-Shock Proteins/metabolism , HSP90 Heat-Shock Proteins/metabolism , Humans , Immunohistochemistry , Liver Neoplasms/pathology , Male , Middle Aged , Tomography, X-Ray Computed
17.
Cancer ; 98(12): 2547-53, 2003 Dec 15.
Article in English | MEDLINE | ID: mdl-14669272

ABSTRACT

BACKGROUND: HER-2/neu is a valuable prognostic marker in primary breast carcinoma. Controversy surrounds the correlation between HER-2/neu expression and other prognostic markers, as has been discussed in preclinical and clinical studies. The objective of the current study was to investigate the probability, calculated using parameters that are assessed routinely in clinical practice, that patients with breast carcinoma had positive HER-2/neu status. METHODS: The authors evaluated HER-2/neu status in 923 consecutive patients with breast carcinoma by immunohistochemical methods. Correlations involving HER-2/neu status, estrogen receptor (ER) and progesterone receptor (PR) status, tumor grade, patient age, lymph node involvement, and tumor size were evaluated using the Mantel-Haenszel chi-square test and the Spearman correlation. The authors created a simple scoring system (i.e., the diagnostic instrument for validation of HER-2/neu score) to define subgroups of patients with breast carcinoma and to determine the likelihood of HER-2/neu positivity. RESULTS: HER-2/neu overexpression was correlated significantly with negative ER (P = 0.0001) and PR status (P = 0.0001), Grade 3 (G3) lesions (P = 0.0001), and young age (P = 0.006). The likelihood of HER-2/neu positivity in a patient with positive ER and PR status and G1/G2 disease was approximately 6.1%. CONCLUSIONS: The authors demonstrated in a large patient series that HER-2/neu overexpression was associated with negative hormone receptor status, G3, and young age. In a subgroup of patients presenting with hormone-responsive and G1/G2 tumors, the likelihood of HER-2/neu overexpression was very small. Therefore, the assessment of HER-2/neu status in this subgroup of patients with breast carcinoma may be considered unnecessary, unless the role of HER-2/neu status in adjuvant treatment has been proven.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/diagnosis , Breast Neoplasms/metabolism , Receptor, ErbB-2/metabolism , Adult , Aged , Carcinoma, Ductal/diagnosis , Carcinoma, Ductal/metabolism , Carcinoma, Lobular/diagnosis , Carcinoma, Lobular/metabolism , DNA Probes , Female , Humans , Immunoenzyme Techniques , In Situ Hybridization, Fluorescence , Karyotyping , Lymph Nodes/pathology , Middle Aged , Neoplasm Staging , Prognosis , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Risk Factors
18.
J Invest Dermatol ; 121(6): 1409-18, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14675191

ABSTRACT

Contrary to our abundant knowledge about the sensitization phase of human contact hypersensitivity, little is known about the cell types orchestrating the effector phase. In order to address this issue, we phenotypically analyzed biopsies from 72 h epicutaneous patch test reactions (n=10) and normal human skin (n=5) for the presence of various leukocyte differentiation antigens. The inflammatory infiltrate was dominated by CD3+/CD4+ T cells with approximately 30% of the cells coexpressing CD25 and CTLA-4, a phenotype consistent with either activated effector or regulatory T cells. In our search for professional antigen-presenting cells, we were surprised to find not only sizeable numbers of CD1a+ dendritic cells and CD1c+ dendritic cells, but also of CD123+, CD45RA+, BDCA-2+, CLA+, and CD62L+ plasmacytoid dendritic cells. Although virtually absent in normal human skin, these cells were detectable already 6 h after hapten challenge and were often found in close proximity to CD56+ natural killer cells, indicative of a functional interaction between these cell types. The detailed knowledge of the cellular composition of the inflammatory infiltrate in allergic contact dermatitis and its kinetics should form the basis for the investigation of the immunologic and molecular events operative in the perpetuation and resolution of the eczematous response.


Subject(s)
Dermatitis, Allergic Contact/immunology , Dermatitis, Allergic Contact/pathology , Langerhans Cells/immunology , Langerhans Cells/pathology , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Biomarkers , CD4 Antigens/analysis , CD56 Antigen/analysis , Dermatitis, Allergic Contact/etiology , Flow Cytometry , Humans , Immunoglobulins/analysis , Immunophenotyping , Interleukin-3 Receptor alpha Subunit , Killer Cells, Natural/chemistry , Killer Cells, Natural/immunology , Kinetics , Membrane Glycoproteins/analysis , Patch Tests , Receptors, Interleukin-2/analysis , Receptors, Interleukin-3/analysis , T-Lymphocyte Subsets/chemistry , T-Lymphocyte Subsets/immunology , CD83 Antigen
19.
Cancer ; 98(10): 2291-301, 2003 Nov 15.
Article in English | MEDLINE | ID: mdl-14601101

ABSTRACT

BACKGROUND: A promising treatment approach for patients with malignant disease that recently has found its way into clinical trials is based on vaccination with autologous dendritic cells loaded with tumor antigens. However, adequate assays for monitoring clinical and immunologic responses still are under debate. In recent years, the determination of angiogenic markers has shown considerable potential in the diagnosis and prognosis of patients with malignant disease, because tumor growth and spread are promoted by angiogenesis, the formation of new blood vessels. METHODS: The authors established a method for measuring the plasma levels of three modulators of angiogenesis: vascular endothelial growth factor, platelet-derived endothelial cell growth factor, and thrombospondin-1. The angiogenic blood profile of a healthy control group was characterized and compared with a group of patients with malignant disease. Ultimately, levels of circulating angiogenic factors were monitored in the course of dendritic cell-based cancer immunotherapy. RESULTS: Baseline levels of angiogenic mediators varied substantially among healthy individuals but showed consistent values for each individual. Blood levels of circulating angiogenic factors were elevated significantly in patients with advanced disease and were highly sensitive to dendritic cell-based immunotherapy. CONCLUSIONS: To our knowledge, the current report was the first to analyze circulating levels of angiogenic factors during dendritic cell-based immunotherapy. The authors observed a noteworthy change in the angiogenic blood profile with treatment, and this change was correlated with the induction of an immunologic response.


Subject(s)
Biomarkers/blood , Cancer Vaccines/pharmacology , Dendritic Cells , Immunotherapy , Neoplasms/immunology , Neoplasms/therapy , Neovascularization, Pathologic , Thrombospondin 1/blood , Thymidine Phosphorylase/blood , Vascular Endothelial Growth Factor A/blood , Adult , Cancer Vaccines/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Treatment Outcome
20.
Int J Oncol ; 23(3): 611-6, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12888895

ABSTRACT

Following isolated limb perfusion (ILP) with hyperthermia (H T), TNF and melphalan, there is immediate tumor softening secondary to augmentation of capillary leak in the tumor neovasculature. TNF can induce vascular permeability but is always used with HT during ILP and the contribution of the latter on permeability is not known. This study characterizes the effects of HT and TNF on vascular permeability in vitro. Permeability across confluent human umbilical vein endothelial cells exposed to HT (40 degrees C) with or without 0.1-1000 ng/ml TNF was assessed by quantitating flux of albumin bound Evan's Blue dye from the upper to lower chamber. Immunofluorescent staining for VE-cadherin and F-actin was performed after human umbilical vein endothelial cells (hUVECs) were exposed to these conditions. HT induced a significant and reversible increase in permeability compared to untreated hUVECs (p<0.001) whereas barrier function was not altered by TNF. Untreated hUVECs had uniform cell surface staining for VE-cadherin, the primary endothelial intercellular adhesion molecule, with colocalization of F-actin cytoskeletal elements. HT resulted in a marked decrease in VE-cadherin staining and contraction of F-actin at sites of endothelial cell-cell separation. These data demonstrate that under conditions relevant to those used in ILP, HT but not TNF contributes to a rapid and reversible change in endothelial cell permeability in association with a down regulation of VE-cadherin. These data support the use of HT in isolation perfusion and demonstrate a novel mechanism for alterations in microvascular permeability by HT.


Subject(s)
Cadherins/metabolism , Capillary Permeability , Down-Regulation , Endothelial Cells/cytology , Endothelium, Vascular/cytology , Hyperthermia, Induced , Tumor Necrosis Factor-alpha/metabolism , Umbilical Veins/cytology , Actins/metabolism , Antigens, CD , Cell Adhesion , Cell Separation , Cells, Cultured , Dose-Response Relationship, Drug , Edetic Acid/pharmacology , Humans , Microcirculation/pathology , Microscopy, Fluorescence , Permeability , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...